Amer Zeidan, MBBS

• Alexa Siddon
• Alexander B. Pine
• Alfred Lee
• Andrew Wang
• Benjamin Y. Lu
• Cary Gross
• Christine Ko
• Cristina Brunet
• Daniel Zelterman
• David Witt
• Erin Medoff
• Francine Foss
• Gauri Panse
• Ian Odell
• Iris Isufi
• Jeanne Hendrickson
• Jonathan Leventhal
• Mina Xu
• Natalia Neparidze
• Nikolai Podoltsev
• Prajwal Boddu
• Ranjit S. Bindra
• Richard Flavell
• Rong Wang
• Rory Shallis
• Sarah Schellhorn Mougalian
• Scott Huntington
• Shuangge Steven Ma
• Stephanie Halene
• Stephanie Prozora
• Stuart Seropian
• Tae Kon Kim
• Terri Parker
• Thomas Prebet
• Toma Tebaldi
• Wei Wei
• Xiao Xu
• Xiaomei Ma

Hematologic Neoplasms; Translational Medical Research

• Injectable Hypomethylating Agents for Management of Myelodysplastic Syndromes: Patients' Perspectives on Treatment.Zeidan AM, Jayade S, Schmier J, Botteman M, Hassan A, Ruiters D, Hill K, Joshi N. Injectable Hypomethylating Agents for Management of Myelodysplastic Syndromes: Patients' Perspectives on Treatment. Clinical Lymphoma, Myeloma & Leukemia 2022, 22: e185-e198. PMID: 34674983, DOI: 10.1016/j.clml.2021.09.009.
• Practice patterns and real-life outcomes for patients with acute promyelocytic leukemia in the United States.Bewersdorf JP, Prozora S, Podoltsev NA, Shallis RM, Huntington SF, Neparidze N, Wang R, Zeidan AM, Davidoff AJ. Practice patterns and real-life outcomes for patients with acute promyelocytic leukemia in the United States. Blood Advances 2022, 6: 376-385. PMID: 34724703, PMCID: PMC8791583, DOI: 10.1182/bloodadvances.2021005642.
• Gilteritinib vs salvage chemotherapy in FLT3-mutated acute myeloid leukemia: number needed to treat for clinical outcomes per a secondary analysis of the ADMIRAL trial.Zeidan AM, Qi CZ, Yang H, Garnham A, Shah MV, Pandya BJ. Gilteritinib vs salvage chemotherapy in FLT3-mutated acute myeloid leukemia: number needed to treat for clinical outcomes per a secondary analysis of the ADMIRAL trial. Leukemia & Lymphoma 2022, 63: 762-764. PMID: 34749571, DOI: 10.1080/10428194.2021.2001467.
• Neutrophil and platelet increases with luspatercept in lower-risk MDS: secondary endpoints from the MEDALIST trial.Garcia-Manero G, Mufti GJ, Fenaux P, Buckstein R, Santini V, Díez-Campelo M, Finelli C, Ilhan O, Sekeres MA, Zeidan AM, Ito R, Zhang J, Rampersad A, Sinsimer D, Backstrom JT, Platzbecker U, Komrokji RS. Neutrophil and platelet increases with luspatercept in lower-risk MDS: secondary endpoints from the MEDALIST trial. Blood 2022, 139: 624-629. PMID: 34758066, PMCID: PMC8796653, DOI: 10.1182/blood.2021012589.
• Phase 1 study of anti-CD47 monoclonal antibody CC-90002 in patients with relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndromes.Zeidan AM, DeAngelo DJ, Palmer J, Seet CS, Tallman MS, Wei X, Raymon H, Sriraman P, Kopytek S, Bewersdorf JP, Burgess MR, Hege K, Stock W. Phase 1 study of anti-CD47 monoclonal antibody CC-90002 in patients with relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndromes. Annals Of Hematology 2022, 101: 557-569. PMID: 34981142, DOI: 10.1007/s00277-021-04734-2.
• A complex karyotype and a genetic mutation in acute myeloid leukaemia.Bewersdorf JP, Siddon A, DiAdamo A, Zeidan AM. A complex karyotype and a genetic mutation in acute myeloid leukaemia. Lancet 2021, 396: 2018. PMID: 33341145, DOI: 10.1016/S0140-6736(20)32543-5.
• Peri-transfusion quality-of-life assessment for patients with myelodysplastic syndromes.Abel GA, Klepin HD, Magnavita ES, Jaung T, Lu W, Shallis RM, Hantel A, Bahl NE, Dellinger-Johnson R, Winer ES, Zeidan AM. Peri-transfusion quality-of-life assessment for patients with myelodysplastic syndromes. Transfusion 2021, 61: 2830-2836. PMID: 34251040, DOI: 10.1111/trf.16584.
• Cost-effectiveness analysis of oral azacitidine maintenance therapy in acute myeloid leukemia.Bewersdorf JP, Patel KK, Huntington SF, Zeidan AM. Cost-effectiveness analysis of oral azacitidine maintenance therapy in acute myeloid leukemia. Blood Advances 2021, 5: 4686-4690. PMID: 34525174, PMCID: PMC8759135, DOI: 10.1182/bloodadvances.2021005472.
• Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial.DiNardo CD, Schuh AC, Stein EM, Montesinos P, Wei AH, de Botton S, Zeidan AM, Fathi AT, Kantarjian HM, Bennett JM, Frattini MG, Martin-Regueira P, Lersch F, Gong J, Hasan M, Vyas P, Döhner H. Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial. The Lancet. Oncology 2021, 22: 1597-1608. PMID: 34672961, DOI: 10.1016/S1470-2045(21)00494-0.
• A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for older patients with AML.Zeidan AM, Boss I, Beach CL, Copeland WB, Thompson E, Fox BA, Hasle VE, Hellmann A, Taussig DC, Tormo M, Voso MT, Cavenagh J, O'Connor T, Previtali A, Rose S, Silverman LR. A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for older patients with AML. Blood Advances 2022, 6: 2219-2229. PMID: 34933333, PMCID: PMC9006260, DOI: 10.1182/bloodadvances.2021006138.
• Clinical outcomes of older patients with AML receiving hypomethylating agents: a large population-based study in the United States.Zeidan AM, Wang R, Wang X, Shallis RM, Podoltsev NA, Bewersdorf JP, Huntington SF, Neparidze N, Giri S, Gore SD, Davidoff AJ, Ma X. Clinical outcomes of older patients with AML receiving hypomethylating agents: a large population-based study in the United States. Blood Advances 2020, 4: 2192-2201. PMID: 32433746, PMCID: PMC7252544, DOI: 10.1182/bloodadvances.2020001779.
• Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts.Zeidan AM, Boddu PC, Patnaik MM, Bewersdorf JP, Stahl M, Rampal RK, Shallis R, Steensma DP, Savona MR, Sekeres MA, Roboz GJ, DeAngelo DJ, Schuh AC, Padron E, Zeidner JF, Walter RB, Onida F, Fathi A, DeZern A, Hobbs G, Stein EM, Vyas P, Wei AH, Bowen DT, Montesinos P, Griffiths EA, Verma AK, Keyzner A, Bar-Natan M, Navada SC, Kremyanskaya M, Goldberg AD, Al-Kali A, Heaney ML, Nazha A, Salman H, Luger S, Pratz KW, Konig H, Komrokji R, Deininger M, Cirici BX, Bhatt VR, Silverman LR, Erba HP, Fenaux P, Platzbecker U, Santini V, Wang ES, Tallman MS, Stone RM, Mascarenhas J. Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts. The Lancet. Haematology 2020, 7: e601-e612. PMID: 32563283, PMCID: PMC7302757, DOI: 10.1016/S2352-3026(20)30205-2.
• Performance of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) score in predicting survival benefit with hypomethylating agent use in patients with relapsed or refractory acute myeloid leukemia.Stahl M, DeVeaux M, Montesinos P, Itzykson R, Ritchie EK, Sekeres MA, Barnard J, Podoltsev NA, Brunner A, Komrokji RS, Bhatt VR, Al-Kali A, Cluzeau T, Santini V, Roboz GJ, Fenaux P, Litzow M, Fathi AT, Perreault S, Kim TK, Prebet T, Vey N, Verma V, Germing U, Bergua J, Serrano J, Gore SD, Zeidan AM. Performance of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) score in predicting survival benefit with hypomethylating agent use in patients with relapsed or refractory acute myeloid leukemia. Leukemia & Lymphoma 2019, 60: 246-249. PMID: 29963936, DOI: 10.1080/10428194.2018.1468893.
• Long-term follow-up of a single institution pilot study of sirolimus, tacrolimus, and short course methotrexate for graft versus host disease prophylaxis in mismatched unrelated donor allogeneic stem cell transplantation.Kim TK, DeVeaux M, Stahl M, Perreault S, Isufi I, Cooper D, Foss F, Shlomchik W, Zelterman D, Zeidan AM, Seropian S. Long-term follow-up of a single institution pilot study of sirolimus, tacrolimus, and short course methotrexate for graft versus host disease prophylaxis in mismatched unrelated donor allogeneic stem cell transplantation. Annals Of Hematology 2019, 98: 237-240. PMID: 30027436, DOI: 10.1007/s00277-018-3427-1.
• Epidemiology of myelodysplastic syndromes: Why characterizing the beast is a prerequisite to taming it.Zeidan AM, Shallis RM, Wang R, Davidoff A, Ma X. Epidemiology of myelodysplastic syndromes: Why characterizing the beast is a prerequisite to taming it. Blood Reviews 2019, 34: 1-15. PMID: 30314642, DOI: 10.1016/j.blre.2018.09.001.
• Systematic review and meta-analysis of the effect of iron chelation therapy on overall survival and disease progression in patients with lower-risk myelodysplastic syndromes.Zeidan AM, Giri S, DeVeaux M, Ballas SK, Duong VH. Systematic review and meta-analysis of the effect of iron chelation therapy on overall survival and disease progression in patients with lower-risk myelodysplastic syndromes. Annals Of Hematology 2019, 98: 339-350. PMID: 30413901, DOI: 10.1007/s00277-018-3539-7.
• Treatment sequence of lenalidomide and hypomethylating agents and the impact on clinical outcomes for patients with myelodysplastic syndromes.Zeidan AM, Klink AJ, McGuire M, Feinberg B. Treatment sequence of lenalidomide and hypomethylating agents and the impact on clinical outcomes for patients with myelodysplastic syndromes. Leukemia & Lymphoma 2019, 60: 2050-2055. PMID: 30636526, DOI: 10.1080/10428194.2018.1551538.
• Will deeper characterization of the landscape of immune checkpoint molecules in acute myeloid leukemia bone marrow lead to improved therapeutic targeting?Vandsemb EN, Kim TK, Zeidan AM. Will deeper characterization of the landscape of immune checkpoint molecules in acute myeloid leukemia bone marrow lead to improved therapeutic targeting? Cancer 2019, 125: 1410-1413. PMID: 30861094, PMCID: PMC6467744, DOI: 10.1002/cncr.32042.
• Impact of Hydroxyurea on Survival and Risk of Thrombosis Among Older Patients With Essential Thrombocythemia.Podoltsev NA, Zhu M, Zeidan AM, Wang R, Wang X, Davidoff AJ, Huntington SF, Giri S, Gore SD, Ma X. Impact of Hydroxyurea on Survival and Risk of Thrombosis Among Older Patients With Essential Thrombocythemia. Journal Of The National Comprehensive Cancer Network : JNCCN 2019, 17: 211-219. PMID: 30865915, DOI: 10.6004/jnccn.2018.7095.
• Myeloid disorders after autoimmune disease.Boddu PC, Zeidan AM. Myeloid disorders after autoimmune disease. Best Practice & Research. Clinical Haematology 2019, 32: 74-88. PMID: 30927978, PMCID: PMC6541412, DOI: 10.1016/j.beha.2019.02.002.
• Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges.Shallis RM, Wang R, Davidoff A, Ma X, Zeidan AM. Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges. Blood Reviews 2019, 36: 70-87. PMID: 31101526, DOI: 10.1016/j.blre.2019.04.005.
• RBC transfusion independence among lower risk MDS patients receiving hypomethylating agents: a population-level analysis.Zeidan AM, Zhu W, Stahl M, Wang R, Huntington SF, Giri S, Podoltsev NA, Gore SD, Ma X, Davidoff AJ. RBC transfusion independence among lower risk MDS patients receiving hypomethylating agents: a population-level analysis. Leukemia & Lymphoma 2019, 60: 3181-3187. PMID: 31170846, DOI: 10.1080/10428194.2019.1622700.
• Underutilization of guideline-recommended supportive care among older adults with multiple myeloma in the United States.Giri S, Zhu W, Wang R, Zeidan A, Podoltsev N, Gore SD, Neparidze N, Ma X, Gross CP, Davidoff AJ, Huntington SF. Underutilization of guideline-recommended supportive care among older adults with multiple myeloma in the United States. Cancer 2019, 125: 4084-4095. PMID: 31381151, DOI: 10.1002/cncr.32428.
• Improved JAK Inhibition in Myelofibrosis-The Long Road Ahead.Stahl M, Zeidan AM. Improved JAK Inhibition in Myelofibrosis-The Long Road Ahead. JAMA Oncology 2018, 4: 659-660. PMID: 29522105, DOI: 10.1001/jamaoncol.2017.5802.
• Hypomethylating agents in myelodysplastic syndromes and population-level outcomes: a changing landscape or a small dent?Zeidan AM. Hypomethylating agents in myelodysplastic syndromes and population-level outcomes: a changing landscape or a small dent? Leukemia & Lymphoma 2018, 59: 1030-1032. PMID: 28952833, DOI: 10.1080/10428194.2017.1382700.
• Lenalidomide in non-deletion 5q lower-risk myelodysplastic syndromes: a glass quarter full or three quarters empty?Shallis RM, Zeidan AM. Lenalidomide in non-deletion 5q lower-risk myelodysplastic syndromes: a glass quarter full or three quarters empty? Leukemia & Lymphoma 2018, 59: 2015-2017. PMID: 29411698, DOI: 10.1080/10428194.2018.1430797.
• More is less, less is more, or does it really matter? The curious case of impact of azacitidine administration schedules on outcomes in patients with myelodysplastic syndromes.Shallis RM, Zeidan AM. More is less, less is more, or does it really matter? The curious case of impact of azacitidine administration schedules on outcomes in patients with myelodysplastic syndromes. BMC Hematology 2018, 18: 4. PMID: 29435332, PMCID: PMC5796398, DOI: 10.1186/s12878-018-0095-2.
• Long-term survival of older patients with MDS treated with HMA therapy without subsequent stem cell transplantation.Zeidan AM, Stahl M, Hu X, Wang R, Huntington SF, Podoltsev NA, Gore SD, Ma X, Davidoff AJ. Long-term survival of older patients with MDS treated with HMA therapy without subsequent stem cell transplantation. Blood 2018, 131: 818-821. PMID: 29259002, PMCID: PMC6410557, DOI: 10.1182/blood-2017-10-811729.
• Allogeneic Hematopoietic Stem Cell Transplantation Following the Use of Hypomethylating Agents among Patients with Relapsed or Refractory AML: Findings from an International Retrospective Study.Stahl M, DeVeaux M, Montesinos P, Itzykson R, Ritchie EK, Sekeres MA, Majhail N, Barnard J, Podoltsev NA, Brunner AM, Komrokji RS, Bhatt VR, Al-Kali A, Cluzeau T, Santini V, Roboz GJ, Fenaux P, Litzow M, Fathi AT, Perreault S, Kim TK, Prebet T, Vey N, Verma V, Kobbe G, Bergua J, Serrano J, Gore SD, Zeidan AM. Allogeneic Hematopoietic Stem Cell Transplantation Following the Use of Hypomethylating Agents among Patients with Relapsed or Refractory AML: Findings from an International Retrospective Study. Biology Of Blood And Marrow Transplantation : Journal Of The American Society For Blood And Marrow Transplantation 2018, 24: 1754-1758. PMID: 29649620, DOI: 10.1016/j.bbmt.2018.03.025.
• Beliefs and practice patterns in hyperleukocytosis management in acute myeloid leukemia: a large U.S. web-based survey.Stahl M, Pine A, Hendrickson JE, Litzow MR, Luger SM, Stone RM, Erba HP, Kim TK, Sekeres MA, Steensma DP, Komrokji RS, Gore SD, Zeidan AM. Beliefs and practice patterns in hyperleukocytosis management in acute myeloid leukemia: a large U.S. web-based survey. Leukemia & Lymphoma 2018, 59: 2723-2726. PMID: 29667455, DOI: 10.1080/10428194.2018.1452219.
• Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort.Stahl M, DeVeaux M, Montesinos P, Itzykson R, Ritchie EK, Sekeres MA, Barnard JD, Podoltsev NA, Brunner AM, Komrokji RS, Bhatt VR, Al-Kali A, Cluzeau T, Santini V, Fathi AT, Roboz GJ, Fenaux P, Litzow MR, Perreault S, Kim TK, Prebet T, Vey N, Verma V, Germing U, Bergua JM, Serrano J, Gore SD, Zeidan AM. Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort. Blood Advances 2018, 2: 923-932. PMID: 29685952, PMCID: PMC5916007, DOI: 10.1182/bloodadvances.2018016121.
• A Multi-center Phase I Trial of Ipilimumab in Patients with Myelodysplastic Syndromes following Hypomethylating Agent Failure.Zeidan AM, Knaus HA, Robinson TM, Towlerton AMH, Warren EH, Zeidner JF, Blackford AL, Duffield AS, Rizzieri D, Frattini MG, Levy YM, Schroeder MA, Ferguson A, Sheldon KE, DeZern AE, Gojo I, Gore SD, Streicher H, Luznik L, Smith BD. A Multi-center Phase I Trial of Ipilimumab in Patients with Myelodysplastic Syndromes following Hypomethylating Agent Failure. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2018, 24: 3519-3527. PMID: 29716921, PMCID: PMC6680246, DOI: 10.1158/1078-0432.CCR-17-3763.
• To chelate or not to chelate in MDS: That is the question!Zeidan AM, Griffiths EA. To chelate or not to chelate in MDS: That is the question! Blood Reviews 2018, 32: 368-377. PMID: 29602612, DOI: 10.1016/j.blre.2018.03.002.
• Inotuzumab ozogamicin in the treatment of relapsed/refractory acute B cell lymphoblastic leukemia.Uy N, Nadeau M, Stahl M, Zeidan AM. Inotuzumab ozogamicin in the treatment of relapsed/refractory acute B cell lymphoblastic leukemia. Journal Of Blood Medicine 2018, 9: 67-74. PMID: 29713210, PMCID: PMC5908210, DOI: 10.2147/JBM.S136575.
• The effect of iron chelation therapy on overall survival in sickle cell disease and β-thalassemia: A systematic review.Ballas SK, Zeidan AM, Duong VH, DeVeaux M, Heeney MM. The effect of iron chelation therapy on overall survival in sickle cell disease and β-thalassemia: A systematic review. American Journal Of Hematology 2018, 93: 943-952. PMID: 29635754, DOI: 10.1002/ajh.25103.
• Counseling patients with higher-risk MDS regarding survival with azacitidine therapy: are we using realistic estimates?Zeidan AM, Stahl M, DeVeaux M, Giri S, Huntington S, Podoltsev N, Wang R, Ma X, Davidoff AJ, Gore SD. Counseling patients with higher-risk MDS regarding survival with azacitidine therapy: are we using realistic estimates? Blood Cancer Journal 2018, 8: 55. PMID: 29891916, PMCID: PMC5995881, DOI: 10.1038/s41408-018-0081-8.
• Immunosuppressive therapy in myelodysplastic syndromes: a borrowed therapy in search of the right place.Shallis RM, Chokr N, Stahl M, Pine AB, Zeidan AM. Immunosuppressive therapy in myelodysplastic syndromes: a borrowed therapy in search of the right place. Expert Review Of Hematology 2018, 11: 715-726. PMID: 30024293, DOI: 10.1080/17474086.2018.1503049.
• The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort.Stahl M, DeVeaux M, de Witte T, Neukirchen J, Sekeres MA, Brunner AM, Roboz GJ, Steensma DP, Bhatt VR, Platzbecker U, Cluzeau T, Prata PH, Itzykson R, Fenaux P, Fathi AT, Smith A, Germing U, Ritchie EK, Verma V, Nazha A, Maciejewski JP, Podoltsev NA, Prebet T, Santini V, Gore SD, Komrokji RS, Zeidan AM. The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort. Blood Advances 2018, 2: 1765-1772. PMID: 30037803, PMCID: PMC6058241, DOI: 10.1182/bloodadvances.2018019414.
• Aplastic anemia: Etiology, molecular pathogenesis, and emerging concepts.Shallis RM, Ahmad R, Zeidan AM. Aplastic anemia: Etiology, molecular pathogenesis, and emerging concepts. European Journal Of Haematology 2018, 101: 711-720. PMID: 30055055, DOI: 10.1111/ejh.13153.
• The genetic and molecular pathogenesis of myelodysplastic syndromes.Shallis RM, Ahmad R, Zeidan AM. The genetic and molecular pathogenesis of myelodysplastic syndromes. European Journal Of Haematology 2018, 101: 260-271. PMID: 29742289, DOI: 10.1111/ejh.13092.
• Conviction in the face of affliction: a case series of Jehovah's Witnesses with myeloid malignancies.Shallis RM, Xu ML, Curtis SA, Medoff E, Mixon R, Folkers A, Zeidan AM. Conviction in the face of affliction: a case series of Jehovah's Witnesses with myeloid malignancies. Annals Of Hematology 2018, 97: 2245-2248. PMID: 30088044, DOI: 10.1007/s00277-018-3459-6.
• Oncologist volume and outcomes in older adults diagnosed with diffuse large B cell lymphoma.Huntington SF, Hoag JR, Zhu W, Wang R, Zeidan AM, Giri S, Podoltsev NA, Gore SD, Ma X, Gross CP, Davidoff AJ. Oncologist volume and outcomes in older adults diagnosed with diffuse large B cell lymphoma. Cancer 2018, 124: 4211-4220. PMID: 30216436, PMCID: PMC6263848, DOI: 10.1002/cncr.31688.
• The impact of phlebotomy and hydroxyurea on survival and risk of thrombosis among older patients with polycythemia vera.Podoltsev NA, Zhu M, Zeidan AM, Wang R, Wang X, Davidoff AJ, Huntington SF, Giri S, Gore SD, Ma X. The impact of phlebotomy and hydroxyurea on survival and risk of thrombosis among older patients with polycythemia vera. Blood Advances 2018, 2: 2681-2690. PMID: 30333100, PMCID: PMC6199652, DOI: 10.1182/bloodadvances.2018021436.
• Wide variations in blood product transfusion practices among providers who care for patients with acute leukemia in the United States.Pine AB, Lee EJ, Sekeres M, Steensma DP, Zelterman D, Prebet T, DeZern A, Komrokji R, Litzow M, Luger S, Stone R, Erba HP, Garcia-Manero G, Lee AI, Podoltsev NA, Barbarotta L, Kasberg S, Hendrickson JE, Gore SD, Zeidan AM. Wide variations in blood product transfusion practices among providers who care for patients with acute leukemia in the United States. Transfusion 2017, 57: 289-295. PMID: 27878822, PMCID: PMC5309168, DOI: 10.1111/trf.13934.
• Risk of myeloid neoplasms after radiotherapy among older women with localized breast cancer: A population-based study.Zeidan AM, Long JB, Wang R, Hu X, Yu JB, Huntington SF, Abel GA, Mougalian SS, Podoltsev NA, Gore SD, Gross CP, Ma X, Davidoff AJ. Risk of myeloid neoplasms after radiotherapy among older women with localized breast cancer: A population-based study. PloS One 2017, 12: e0184747. PMID: 28902882, PMCID: PMC5597231, DOI: 10.1371/journal.pone.0184747.
• Immunotherapeutic Concepts to Target Acute Myeloid Leukemia: Focusing on the Role of Monoclonal Antibodies, Hypomethylating Agents and the Leukemic Microenvironment.Gbolahan OB, Zeidan AM, Stahl M, Abu Zaid M, Farag S, Paczesny S, Konig H. Immunotherapeutic Concepts to Target Acute Myeloid Leukemia: Focusing on the Role of Monoclonal Antibodies, Hypomethylating Agents and the Leukemic Microenvironment. International Journal Of Molecular Sciences 2017, 18 PMID: 28758974, PMCID: PMC5578050, DOI: 10.3390/ijms18081660.
• Rheumatologic Manifestations of Hematologic Neoplasms.Wang A, Zeidan A, Brunet C. Rheumatologic Manifestations of Hematologic Neoplasms. Current Rheumatology Reviews 2017, 13: 51-58. PMID: 27527358, DOI: 10.2174/1573397112666160815125148.
• Health Care Use by Older Adults With Acute Myeloid Leukemia at the End of Life.Wang R, Zeidan AM, Halene S, Xu X, Davidoff AJ, Huntington SF, Podoltsev NA, Gross CP, Gore SD, Ma X. Health Care Use by Older Adults With Acute Myeloid Leukemia at the End of Life. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2017, 35: 3417-3424. PMID: 28783450, PMCID: PMC5648174, DOI: 10.1200/JCO.2017.72.7149.
• Cost-effectiveness analysis of consolidation with brentuximab vedotin for high-risk Hodgkin lymphoma after autologous stem cell transplantation.Hui L, von Keudell G, Wang R, Zeidan AM, Gore SD, Ma X, Davidoff AJ, Huntington SF. Cost-effectiveness analysis of consolidation with brentuximab vedotin for high-risk Hodgkin lymphoma after autologous stem cell transplantation. Cancer 2017, 123: 3763-3771. PMID: 28640385, PMCID: PMC5610636, DOI: 10.1002/cncr.30818.
• Hypomethylating agent therapy use and survival in older patients with chronic myelomonocytic leukemia in the United States: A large population-based study.Zeidan AM, Hu X, Long JB, Wang R, Ma X, Podoltsev NA, Huntington SF, Gore SD, Davidoff AJ. Hypomethylating agent therapy use and survival in older patients with chronic myelomonocytic leukemia in the United States: A large population-based study. Cancer 2017, 123: 3754-3762. PMID: 28621841, PMCID: PMC6540984, DOI: 10.1002/cncr.30814.
• Management of lower-risk myelodysplastic syndromes without del5q: current approach and future trends.Stahl M, Zeidan AM. Management of lower-risk myelodysplastic syndromes without del5q: current approach and future trends. Expert Review Of Hematology 2017, 10: 345-364. PMID: 28277851, DOI: 10.1080/17474086.2017.1297704.
• A call for action: Increasing enrollment of untreated patients with higher-risk myelodysplastic syndromes in first-line clinical trials.Zeidan AM, Stahl M, Sekeres MA, Steensma DP, Komrokji RS, Gore SD. A call for action: Increasing enrollment of untreated patients with higher-risk myelodysplastic syndromes in first-line clinical trials. Cancer 2017, 123: 3662-3672. PMID: 28759108, DOI: 10.1002/cncr.30903.
• Modest improvement in survival of patients with refractory anemia with excess blasts in the hypomethylating agents era in the United States.Zeidan AM, Wang R, Gross CP, Gore SD, Huntington SF, Prebet T, Abel GA, Davidoff AJ, Ma X. Modest improvement in survival of patients with refractory anemia with excess blasts in the hypomethylating agents era in the United States. Leukemia & Lymphoma 2017, 58: 982-985. PMID: 27558206, DOI: 10.1080/10428194.2016.1214954.
• Reactive granulomatous dermatitis presenting as subcutaneous nodules and cords in a patient with advanced myelodysplastic syndrome.Weed J, Ko C, Stahl M, Much M, Witt D, Zeidan AM, Leventhal J. Reactive granulomatous dermatitis presenting as subcutaneous nodules and cords in a patient with advanced myelodysplastic syndrome. Annals Of Hematology 2017, 96: 1037-1039. PMID: 28220192, DOI: 10.1007/s00277-017-2954-5.
• Hypomethylating agents in combination with histone deacetylase inhibitors in higher risk myelodysplastic syndromes: Is there a light at the end of the tunnel?Stahl M, Zeidan AM. Hypomethylating agents in combination with histone deacetylase inhibitors in higher risk myelodysplastic syndromes: Is there a light at the end of the tunnel? Cancer 2017, 123: 911-914. PMID: 28094843, DOI: 10.1002/cncr.30532.
• The skin as a window to the blood: Cutaneous manifestations of myeloid malignancies.Li AW, Yin ES, Stahl M, Kim TK, Panse G, Zeidan AM, Leventhal JS. The skin as a window to the blood: Cutaneous manifestations of myeloid malignancies. Blood Reviews 2017, 31: 370-388. PMID: 28732587, DOI: 10.1016/j.blre.2017.07.003.
• Lenalidomide use in myelodysplastic syndromes: Insights into the biologic mechanisms and clinical applications.Stahl M, Zeidan AM. Lenalidomide use in myelodysplastic syndromes: Insights into the biologic mechanisms and clinical applications. Cancer 2017, 123: 1703-1713. PMID: 28192601, DOI: 10.1002/cncr.30585.
• Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.Greenberg PL, Stone RM, Al-Kali A, Barta SK, Bejar R, Bennett JM, Carraway H, De Castro CM, Deeg HJ, DeZern AE, Fathi AT, Frankfurt O, Gaensler K, Garcia-Manero G, Griffiths EA, Head D, Horsfall R, Johnson RA, Juckett M, Klimek VM, Komrokji R, Kujawski LA, Maness LJ, O'Donnell MR, Pollyea DA, Shami PJ, Stein BL, Walker AR, Westervelt P, Zeidan A, Shead DA, Smith C. Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. Journal Of The National Comprehensive Cancer Network : JNCCN 2017, 15: 60-87. PMID: 28040720, DOI: 10.6004/jnccn.2017.0007.
• Risk stratification in therapy-related myelodysplastic syndromes.Zeidan AM. Risk stratification in therapy-related myelodysplastic syndromes. Oncotarget 2017, 8: 80103-80104. PMID: 29113285, PMCID: PMC5655180, DOI: 10.18632/oncotarget.21178.
• US Food and Drug Administration Black Box Warning and Its Impact on the Use of Erythropoiesis-Stimulating Agents: Thinking Outside the Box.Zeidan AM, Gore SD, Davidoff AJ. US Food and Drug Administration Black Box Warning and Its Impact on the Use of Erythropoiesis-Stimulating Agents: Thinking Outside the Box. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2017, 35: 3264. PMID: 28787256, DOI: 10.1200/JCO.2017.74.3104.
• Overcoming barriers to treating iron overload in patients with lower-risk myelodysplastic syndrome.Zeidan AM, Pullarkat VA, Komrokji RS. Overcoming barriers to treating iron overload in patients with lower-risk myelodysplastic syndrome. Critical Reviews In Oncology/hematology 2017, 117: 57-66. PMID: 28807236, DOI: 10.1016/j.critrevonc.2017.07.002.
• A phase 2 trial of high dose lenalidomide in patients with relapsed/refractory higher-risk myelodysplastic syndromes and acute myeloid leukaemia with trilineage dysplasia.Zeidan AM, Smith BD, Carraway HE, Gojo I, DeZern A, Gore SD. A phase 2 trial of high dose lenalidomide in patients with relapsed/refractory higher-risk myelodysplastic syndromes and acute myeloid leukaemia with trilineage dysplasia. British Journal Of Haematology 2017, 176: 241-247. PMID: 27790720, DOI: 10.1111/bjh.14407.
• Selecting initial treatment of acute myeloid leukaemia in older adults.Podoltsev NA, Stahl M, Zeidan AM, Gore SD. Selecting initial treatment of acute myeloid leukaemia in older adults. Blood Reviews 2017, 31: 43-62. PMID: 27745715, DOI: 10.1016/j.blre.2016.09.005.
• Novel Therapies for Acute Myeloid Leukemia: Are We Finally Breaking the Deadlock?Stahl M, Lu BY, Kim TK, Zeidan AM. Novel Therapies for Acute Myeloid Leukemia: Are We Finally Breaking the Deadlock? Targeted Oncology 2017, 12: 413-447. PMID: 28664386, DOI: 10.1007/s11523-017-0503-8.
• Differential response to hypomethylating agents based on sex: a report on behalf of the MDS Clinical Research Consortium (MDS CRC).DeZern AE, Zeidan AM, Barnard J, Hand W, Al Ali N, Brown F, Zimmerman C, Roboz GJ, Garcia-Manero G, Steensma DP, Komrokji RS, Sekeres MA. Differential response to hypomethylating agents based on sex: a report on behalf of the MDS Clinical Research Consortium (MDS CRC). Leukemia & Lymphoma 2017, 58: 1325-1331. PMID: 27774847, PMCID: PMC5394924, DOI: 10.1080/10428194.2016.1246726.
• Myelodysplastic Syndromes and Acute Myeloid Leukemia After Radiotherapy for Prostate Cancer: A Population-Based Study.Wang R, Zeidan AM, Yu JB, Soulos PR, Davidoff AJ, Gore SD, Huntington SF, Gross CP, Ma X. Myelodysplastic Syndromes and Acute Myeloid Leukemia After Radiotherapy for Prostate Cancer: A Population-Based Study. The Prostate 2017, 77: 437-445. PMID: 27868212, PMCID: PMC5785924, DOI: 10.1002/pros.23281.
• Therapy-related myelodysplastic syndromes, or are they?Abou Zahr A, Kavi AM, Mukherjee S, Zeidan AM. Therapy-related myelodysplastic syndromes, or are they? Blood Reviews 2017, 31: 119-128. PMID: 27923516, DOI: 10.1016/j.blre.2016.11.002.
• Management of myelofibrosis: JAK inhibition and beyond.Stahl M, Zeidan AM. Management of myelofibrosis: JAK inhibition and beyond. Expert Review Of Hematology 2017, 10: 459-477. PMID: 28395559, DOI: 10.1080/17474086.2017.1317590.
• Aplastic Anemia and MDS International Foundation (AAMDSIF): Bone marrow failure disease scientific symposium 2016.Zeidan AM, Battiwalla M, Berlyne D, Winkler T. Aplastic Anemia and MDS International Foundation (AAMDSIF): Bone marrow failure disease scientific symposium 2016. Leukemia Research 2017, 53: 8-12. PMID: 27923195, PMCID: PMC7731993, DOI: 10.1016/j.leukres.2016.11.011.
• The importance of erythroblast enumeration in myeloid neoplasia.Zeidan AM, Xu M, Steensma DP. The importance of erythroblast enumeration in myeloid neoplasia. Annals Of Hematology 2017, 96: 329-330. PMID: 27771743, DOI: 10.1007/s00277-016-2862-0.
• Comparison of clinical outcomes and prognostic utility of risk stratification tools in patients with therapy-related vs de novo myelodysplastic syndromes: a report on behalf of the MDS Clinical Research Consortium.Zeidan AM, Al Ali N, Barnard J, Padron E, Lancet JE, Sekeres MA, Steensma DP, DeZern A, Roboz G, Jabbour E, Garcia-Manero G, List A, Komrokji R. Comparison of clinical outcomes and prognostic utility of risk stratification tools in patients with therapy-related vs de novo myelodysplastic syndromes: a report on behalf of the MDS Clinical Research Consortium. Leukemia 2017, 31: 1391-1397. PMID: 28111463, DOI: 10.1038/leu.2017.33.
• Emerging biological therapies for the treatment of myelodysplastic syndromes.Zeidan AM, Stahl M, Komrokji R. Emerging biological therapies for the treatment of myelodysplastic syndromes. Expert Opinion On Emerging Drugs 2016, 21: 283-300. PMID: 27486848, DOI: 10.1080/14728214.2016.1220534.
• Azacitidine with or without Entinostat for the treatment of therapy-related myeloid neoplasm: further results of the E1905 North American Leukemia Intergroup study.Prebet T, Sun Z, Ketterling RP, Zeidan A, Greenberg P, Herman J, Juckett M, Smith MR, Malick L, Paietta E, Czader M, Figueroa M, Gabrilove J, Erba HP, Tallman MS, Litzow M, Gore SD. Azacitidine with or without Entinostat for the treatment of therapy-related myeloid neoplasm: further results of the E1905 North American Leukemia Intergroup study. British Journal Of Haematology 2016, 172: 384-91. PMID: 26577691, PMCID: PMC4794257, DOI: 10.1111/bjh.13832.
• Comparison of risk stratification tools in predicting outcomes of patients with higher-risk myelodysplastic syndromes treated with azanucleosides.Zeidan AM, Sekeres MA, Garcia-Manero G, Steensma DP, Zell K, Barnard J, Ali NA, Zimmerman C, Roboz G, DeZern A, Nazha A, Jabbour E, Kantarjian H, Gore SD, Maciejewski JP, List A, Komrokji R. Comparison of risk stratification tools in predicting outcomes of patients with higher-risk myelodysplastic syndromes treated with azanucleosides. Leukemia 2016, 30: 649-57. PMID: 26464171, PMCID: PMC4775363, DOI: 10.1038/leu.2015.283.
• Clinical response to ruxolitinib in CSF3R T618-mutated chronic neutrophilic leukemia.Stahl M, Xu ML, Steensma DP, Rampal R, Much M, Zeidan AM. Clinical response to ruxolitinib in CSF3R T618-mutated chronic neutrophilic leukemia. Annals Of Hematology 2016, 95: 1197-200. PMID: 27068405, PMCID: PMC7479634, DOI: 10.1007/s00277-016-2664-4.
• The evolving field of prognostication and risk stratification in MDS: Recent developments and future directions.Lee EJ, Podoltsev N, Gore SD, Zeidan AM. The evolving field of prognostication and risk stratification in MDS: Recent developments and future directions. Blood Reviews 2016, 30: 1-10. PMID: 26119927, DOI: 10.1016/j.blre.2015.06.004.
• Intensity of end-of-life care for patients with myelodysplastic syndromes: Findings from a large national database.Fletcher SA, Cronin AM, Zeidan AM, Odejide OO, Gore SD, Davidoff AJ, Steensma DP, Abel GA. Intensity of end-of-life care for patients with myelodysplastic syndromes: Findings from a large national database. Cancer 2016, 122: 1209-15. PMID: 26914833, DOI: 10.1002/cncr.29913.
• Disease-related costs of care and survival among Medicare-enrolled patients with myelodysplastic syndromes.Zeidan AM, Wang R, Davidoff AJ, Ma S, Zhao Y, Gore SD, Gross CP, Ma X. Disease-related costs of care and survival among Medicare-enrolled patients with myelodysplastic syndromes. Cancer 2016, 122: 1598-607. PMID: 26970288, PMCID: PMC5509410, DOI: 10.1002/cncr.29945.
• Update on acute myeloid leukemia stem cells: New discoveries and therapeutic opportunities.Stahl M, Kim TK, Zeidan AM. Update on acute myeloid leukemia stem cells: New discoveries and therapeutic opportunities. World Journal Of Stem Cells 2016, 8: 316-331. PMID: 27822339, PMCID: PMC5080639, DOI: 10.4252/wjsc.v8.i10.316.
• The Interactions Between Diabetes Mellitus and Myelodysplastic Syndromes: Current State of Evidence and Future Directions.Hamoudeh E, Zeidan AM, Barbarotta L, Rosano N. The Interactions Between Diabetes Mellitus and Myelodysplastic Syndromes: Current State of Evidence and Future Directions. Current Diabetes Reviews 2016, 12: 231-9. PMID: 26008639, DOI: 10.2174/1573399811666150526151241.
• Comparative clinical effectiveness of azacitidine versus decitabine in older patients with myelodysplastic syndromes.Zeidan AM, Davidoff AJ, Long JB, Hu X, Wang R, Ma X, Gross CP, Abel GA, Huntington SF, Podoltsev NA, Hajime U, Prebet T, Gore SD. Comparative clinical effectiveness of azacitidine versus decitabine in older patients with myelodysplastic syndromes. British Journal Of Haematology 2016, 175: 829-840. PMID: 27650975, DOI: 10.1111/bjh.14305.
• Economic burden associated with acute myeloid leukemia treatment.Zeidan AM, Mahmoud D, Kucmin-Bemelmans IT, Alleman CJ, Hensen M, Skikne B, Smith BD. Economic burden associated with acute myeloid leukemia treatment. Expert Review Of Hematology 2016, 9: 79-89. PMID: 26568358, DOI: 10.1586/17474086.2016.1112735.
• Variations in erythropoiesis-stimulating agent administration in transfusion-dependent myelodysplastic syndromes impact response.Duong VH, Baer MR, Hendrick F, Weiss SR, Sato M, Zeidan AM, Gore SD, Davidoff AJ. Variations in erythropoiesis-stimulating agent administration in transfusion-dependent myelodysplastic syndromes impact response. Leukemia Research 2015, 39: 586-91. PMID: 25869077, PMCID: PMC4441842, DOI: 10.1016/j.leukres.2015.03.013.
• Leukaemic vasculitis with myelodysplastic syndrome.Odell ID, Zeidan AM, Parker TL, Colegio OR, Subtil A. Leukaemic vasculitis with myelodysplastic syndrome. Lancet 2015, 386: 501-2. PMID: 26251396, DOI: 10.1016/S0140-6736(15)61165-5.
• Molecular Testing in Myelodysplastic Syndromes for the Practicing Oncologist: Will the Progress Fulfill the Promise?Nazha A, Sekeres MA, Gore SD, Zeidan AM. Molecular Testing in Myelodysplastic Syndromes for the Practicing Oncologist: Will the Progress Fulfill the Promise? The Oncologist 2015, 20: 1069-76. PMID: 26194858, PMCID: PMC4571815, DOI: 10.1634/theoncologist.2015-0067.
• Genome sequencing in myelodysplastic syndromes: can molecular mutations predict benefit from hypomethylating agent therapy?Lee EJ, Zeidan AM. Genome sequencing in myelodysplastic syndromes: can molecular mutations predict benefit from hypomethylating agent therapy? Expert Review Of Hematology 2015, 8: 155-8. PMID: 25697572, DOI: 10.1586/17474086.2015.1016905.
• Comparing the Prognostic Value of Risk stratifying Models for Patients with Lower-Risk Myelodysplastic Syndromes: Is one model better?Zeidan AM, Sekeres MA, Wang XF, Al Ali N, Garcia-Manero G, Steensma DP, Roboz G, Barnard J, Padron E, Dezern A, Maciejewski JP, List AF, Komrokji RS. Comparing the Prognostic Value of Risk stratifying Models for Patients with Lower-Risk Myelodysplastic Syndromes: Is one model better? American Journal Of Hematology 2015 PMID: 26260295, PMCID: PMC4751065, DOI: 10.1002/ajh.24170.
• Lenalidomide Treatment for Lower Risk Nondeletion 5q Myelodysplastic Syndromes Patients Yields Higher Response Rates When Used Before Azacitidine.Zeidan AM, Al Ali NH, Padron E, Lancet J, List A, Komrokji RS. Lenalidomide Treatment for Lower Risk Nondeletion 5q Myelodysplastic Syndromes Patients Yields Higher Response Rates When Used Before Azacitidine. Clinical Lymphoma, Myeloma & Leukemia 2015, 15: 705-10. PMID: 26440749, DOI: 10.1016/j.clml.2015.08.083.
• The clinical use of DNA methyltransferase inhibitors in myelodysplastic syndromes.Abou Zahr A, Saad Aldin E, Barbarotta L, Podoltsev N, Zeidan AM. The clinical use of DNA methyltransferase inhibitors in myelodysplastic syndromes. Expert Review Of Anticancer Therapy 2015, 15: 1019-36. PMID: 26292903, DOI: 10.1586/14737140.2015.1061936.
• Real-life experience of a brief arsenic trioxide-based consolidation chemotherapy in the management of acute promyelocytic leukemia: favorable outcomes with limited anthracycline exposure and shorter consolidation therapy.Leech M, Morris L, Stewart M, Smith BD, Bashey A, Holland K, Solomon S, Zhang X, Carraway HE, Pratz K, Gore SD, Zeidan AM. Real-life experience of a brief arsenic trioxide-based consolidation chemotherapy in the management of acute promyelocytic leukemia: favorable outcomes with limited anthracycline exposure and shorter consolidation therapy. Clinical Lymphoma, Myeloma & Leukemia 2015, 15: 292-7. PMID: 25499624, PMCID: PMC4409502, DOI: 10.1016/j.clml.2014.11.001.
• Comparing the prognostic value of risk stratifying models for patients with lower-risk myelodysplastic syndromes: Is one model better?Zeidan AM, Sekeres MA, Wang XF, Al Ali N, Garcia-Manero G, Steensma DP, Roboz G, Barnard J, Padron E, DeZern A, Maciejewski JP, List AF, Komrokji RS. Comparing the prognostic value of risk stratifying models for patients with lower-risk myelodysplastic syndromes: Is one model better? American Journal Of Hematology 2015, 90: 1036-40. PMID: 26284571, DOI: 10.1002/ajh.24173.
• Deferasirox therapy is associated with reduced mortality risk in a medicare population with myelodysplastic syndromes.Zeidan AM, Hendrick F, Friedmann E, Baer MR, Gore SD, Sasane M, Paley C, Davidoff AJ. Deferasirox therapy is associated with reduced mortality risk in a medicare population with myelodysplastic syndromes. Journal Of Comparative Effectiveness Research 2015, 4: 327-40. PMID: 26274794, PMCID: PMC5549705, DOI: 10.2217/cer.15.20.
• Current state of prognostication and risk stratification in myelodysplastic syndromes.Zeidan AM, Gore SD, Padron E, Komrokji RS. Current state of prognostication and risk stratification in myelodysplastic syndromes. Current Opinion In Hematology 2015, 22: 146-54. PMID: 25575032, DOI: 10.1097/MOH.0000000000000110.
• Patient cost sharing and receipt of erythropoiesis-stimulating agents through medicare part D.Davidoff AJ, Hendrick FB, Zeidan AM, Baer MR, Stuart BC, Shenolikar RA, Gore SD. Patient cost sharing and receipt of erythropoiesis-stimulating agents through medicare part D. Journal Of Oncology Practice / American Society Of Clinical Oncology 2015, 11: e190-8. PMID: 25563701, PMCID: PMC4371123, DOI: 10.1200/JOP.2014.001527.
• Epigenetic Therapy in Acute Myeloid Leukemia: Current and Future Directions.Kim TK, Gore SD, Zeidan AM. Epigenetic Therapy in Acute Myeloid Leukemia: Current and Future Directions. Seminars In Hematology 2015, 52: 172-83. PMID: 26111464, PMCID: PMC5785931, DOI: 10.1053/j.seminhematol.2015.04.003.
• Patterns of Venous Thromboembolism Prophylaxis During Treatment of Acute Leukemia: Results of a North American Web-Based Survey.Lee EJ, Smith BD, Merrey JW, Lee AI, Podoltsev NA, Barbarotta L, Litzow MR, Prebet T, Luger SM, Gore S, Streiff MB, Zeidan AM. Patterns of Venous Thromboembolism Prophylaxis During Treatment of Acute Leukemia: Results of a North American Web-Based Survey. Clinical Lymphoma, Myeloma & Leukemia 2015, 15: 766-770. PMID: 26363982, PMCID: PMC4663156, DOI: 10.1016/j.clml.2015.07.637.
• Case report of a patient with left ventricular assistance device undergoing chemotherapy for a new diagnosis of lung cancer.Khan M, Wasim A, Mirrakhimov AE, McMahon BA, Judge DP, Chu LC, Banavali A, Zeidan AM. Case report of a patient with left ventricular assistance device undergoing chemotherapy for a new diagnosis of lung cancer. Case Reports In Oncological Medicine 2015, 2015: 163727. PMID: 25874142, PMCID: PMC4385621, DOI: 10.1155/2015/163727.
• Clinical utility of lenalidomide in the treatment of myelodysplastic syndromes.Abou Zahr A, Saad Aldin E, Komrokji RS, Zeidan AM. Clinical utility of lenalidomide in the treatment of myelodysplastic syndromes. Journal Of Blood Medicine 2015, 6: 1-16. PMID: 25565910, PMCID: PMC4278786, DOI: 10.2147/JBM.S50482.
• Eliminating Health Care Disparities With Mandatory Clinical Decision Support: The Venous Thromboembolism (VTE) Example.Lau BD, Haider AH, Streiff MB, Lehmann CU, Kraus PS, Hobson DB, Kraenzlin FS, Zeidan AM, Pronovost PJ, Haut ER. Eliminating Health Care Disparities With Mandatory Clinical Decision Support: The Venous Thromboembolism (VTE) Example. Medical Care 2015, 53: 18-24. PMID: 25373403, PMCID: PMC4262632, DOI: 10.1097/MLR.0000000000000251.
• Platelet count doubling after the first cycle of azacitidine therapy predicts eventual response and survival in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukaemia but does not add to prognostic utility of the revised IPSS.Zeidan AM, Lee JW, Prebet T, Greenberg P, Sun Z, Juckett M, Smith MR, Paietta E, Gabrilove J, Erba HP, Katterling RP, Tallman MS, Gore SD. Platelet count doubling after the first cycle of azacitidine therapy predicts eventual response and survival in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukaemia but does not add to prognostic utility of the revised IPSS. British Journal Of Haematology 2014, 167: 62-8. PMID: 24995683, PMCID: PMC4299466, DOI: 10.1111/bjh.13008.
• Spontaneous splenic rupture during induction chemotherapy for acute myeloid leukemia.Zeidan AM, Mitchell M, Khatri R, Itani D, Boikos S, Bose S, Lipsett P, Efron D, King KE, Gerber J, DeZern A. Spontaneous splenic rupture during induction chemotherapy for acute myeloid leukemia. Leukemia & Lymphoma 2014, 55: 209-12. PMID: 23597139, PMCID: PMC4086625, DOI: 10.3109/10428194.2013.796060.
• Venous thromboembolism prophylaxis in hematopoietic stem cell transplantation patients: an international web-based survey of healthcare providers.Zeidan AM, Wellman J, Forde PM, Bolaños-Meade J, Streiff MB. Venous thromboembolism prophylaxis in hematopoietic stem cell transplantation patients: an international web-based survey of healthcare providers. Journal Of Thrombosis And Thrombolysis 2014, 37: 524-6. PMID: 24092259, PMCID: PMC4086620, DOI: 10.1007/s11239-013-1002-0.
• Beyond hypomethylating agents failure in patients with myelodysplastic syndromes.Zeidan AM, Kharfan-Dabaja MA, Komrokji RS. Beyond hypomethylating agents failure in patients with myelodysplastic syndromes. Current Opinion In Hematology 2014, 21: 123-30. PMID: 24335709, PMCID: PMC4124617, DOI: 10.1097/MOH.0000000000000016.
• HLA-haploidentical donor lymphocyte infusions for patients with relapsed hematologic malignancies after related HLA-haploidentical bone marrow transplantation.Zeidan AM, Forde PM, Symons H, Chen A, Smith BD, Pratz K, Carraway H, Gladstone DE, Fuchs EJ, Luznik L, Jones RJ, Bolaños-Meade J. HLA-haploidentical donor lymphocyte infusions for patients with relapsed hematologic malignancies after related HLA-haploidentical bone marrow transplantation. Biology Of Blood And Marrow Transplantation : Journal Of The American Society For Blood And Marrow Transplantation 2014, 20: 314-8. PMID: 24296490, PMCID: PMC4010132, DOI: 10.1016/j.bbmt.2013.11.020.
• An update on type 2B von Willebrand disease.Mikhail S, Aldin ES, Streiff M, Zeidan A. An update on type 2B von Willebrand disease. Expert Review Of Hematology 2014, 7: 217-31. PMID: 24521271, DOI: 10.1586/17474086.2014.868771.
• Is diabetes mellitus associated with increased incidence and disease-specific mortality in endometrial cancer? A systematic review and meta-analysis of cohort studies.Liao C, Zhang D, Mungo C, Tompkins DA, Zeidan AM. Is diabetes mellitus associated with increased incidence and disease-specific mortality in endometrial cancer? A systematic review and meta-analysis of cohort studies. Gynecologic Oncology 2014, 135: 163-71. PMID: 25072931, PMCID: PMC4404750, DOI: 10.1016/j.ygyno.2014.07.095.
• Hepatocellular carcinoma: systemic therapies and future perspectives.Mikhail S, Cosgrove D, Zeidan A. Hepatocellular carcinoma: systemic therapies and future perspectives. Expert Review Of Anticancer Therapy 2014, 14: 1205-18. PMID: 25199765, DOI: 10.1586/14737140.2014.949246.
• Stem cells in gastrointestinal cancers: The road less travelled.Mikhail S, Zeidan A. Stem cells in gastrointestinal cancers: The road less travelled. World Journal Of Stem Cells 2014, 6: 606-13. PMID: 25426257, PMCID: PMC4178260, DOI: 10.4252/wjsc.v6.i5.606.
• Phase 1 dose escalation trial of volasertib in combination with decitabine in patients with acute myeloid leukemia.Cortes J, Podoltsev N, Kantarjian H, Borthakur G, Zeidan AM, Stahl M, Taube T, Fagan N, Rajeswari S, Uy GL. Phase 1 dose escalation trial of volasertib in combination with decitabine in patients with acute myeloid leukemia. International Journal Of Hematology 2021, 113: 92-99. PMID: 32951163, DOI: 10.1007/s12185-020-02994-8.
• Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia.DiNardo CD, Stein AS, Stein EM, Fathi AT, Frankfurt O, Schuh AC, Döhner H, Martinelli G, Patel PA, Raffoux E, Tan P, Zeidan AM, de Botton S, Kantarjian HM, Stone RM, Frattini MG, Lersch F, Gong J, Gianolio DA, Zhang V, Franovic A, Fan B, Goldwasser M, Daigle S, Choe S, Wu B, Winkler T, Vyas P. Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2021, 39: 57-65. PMID: 33119479, PMCID: PMC7771719, DOI: 10.1200/JCO.20.01632.
• A Phase Ib Study of Onvansertib, a Novel Oral PLK1 Inhibitor, in Combination Therapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia.Zeidan AM, Ridinger M, Lin TL, Becker PS, Schiller GJ, Patel PA, Spira AI, Tsai ML, Samuëlsz E, Silberman SL, Erlander M, Wang ES. A Phase Ib Study of Onvansertib, a Novel Oral PLK1 Inhibitor, in Combination Therapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2020, 26: 6132-6140. PMID: 32998961, DOI: 10.1158/1078-0432.CCR-20-2586.
• Patterns of care and clinical outcomes with cytarabine-anthracycline induction chemotherapy for AML patients in the United States.Zeidan AM, Podoltsev NA, Wang X, Zhang C, Bewersdorf JP, Shallis RM, Huntington SF, Neparidze N, Giri S, Gore SD, Davidoff AJ, Ma X, Wang R. Patterns of care and clinical outcomes with cytarabine-anthracycline induction chemotherapy for AML patients in the United States. Blood Advances 2020, 4: 1615-1623. PMID: 32311013, PMCID: PMC7189301, DOI: 10.1182/bloodadvances.2020001728.
• Patterns of care and clinical outcomes of patients with newly diagnosed acute myeloid leukemia presenting with hyperleukocytosis who do not receive intensive chemotherapy.Shallis RM, Stahl M, Wei W, Montesinos P, Lengline E, Neukirchen J, Bhatt VR, Sekeres MA, Fathi AT, Konig H, Luger S, Khan I, Roboz GJ, Cluzeau T, Martínez-Cuadron D, Raffoux E, Germing U, Umakanthan JM, Mukhereje S, Brunner AM, Miller A, McMahon CM, Ritchie EK, Rodríguez-Veiga R, Itzykson R, Boluda B, Rabian F, Tormo M, Acuña-Cruz E, Rabinovich E, Yoo B, Cano I, Podoltsev NA, Bewersdorf JP, Gore S, Zeidan AM. Patterns of care and clinical outcomes of patients with newly diagnosed acute myeloid leukemia presenting with hyperleukocytosis who do not receive intensive chemotherapy. Leukemia & Lymphoma 2020, 61: 1220-1225. PMID: 32100599, PMCID: PMC8273667, DOI: 10.1080/10428194.2020.1728753.
• Wide variation in use and interpretation of gene mutation profiling panels among health care providers of patients with myelodysplastic syndromes: results of a large web-based survey.Pine AB, Chokr N, Stahl M, Steensma DP, Sekeres MA, Litzow MR, Luger SM, Stone RM, Greenberg PL, Bejar R, Bewersdorf JP, Gore SD, Zeidan AM. Wide variation in use and interpretation of gene mutation profiling panels among health care providers of patients with myelodysplastic syndromes: results of a large web-based survey. Leukemia & Lymphoma 2020, 61: 1455-1464. PMID: 32026740, DOI: 10.1080/10428194.2020.1723013.
• Management of hyperleukocytosis and impact of leukapheresis among patients with acute myeloid leukemia (AML) on short- and long-term clinical outcomes: a large, retrospective, multicenter, international study.Stahl M, Shallis RM, Wei W, Montesinos P, Lengline E, Neukirchen J, Bhatt VR, Sekeres MA, Fathi AT, Konig H, Luger S, Khan I, Roboz GJ, Cluzeau T, Martínez-Cuadron D, Raffoux E, Germing U, Umakanthan JM, Mukherjee S, Brunner AM, Miller A, McMahon CM, Ritchie EK, Rodríguez-Veiga R, Itzykson R, Boluda B, Rabian F, Tormo M, Acuña-Cruz E, Rabinovich E, Yoo B, Cano I, Podoltsev NA, Bewersdorf JP, Gore S, Zeidan AM. Management of hyperleukocytosis and impact of leukapheresis among patients with acute myeloid leukemia (AML) on short- and long-term clinical outcomes: a large, retrospective, multicenter, international study. Leukemia 2020, 34: 3149-3160. PMID: 32132655, PMCID: PMC8155811, DOI: 10.1038/s41375-020-0783-3.
• Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes.Fenaux P, Platzbecker U, Mufti GJ, Garcia-Manero G, Buckstein R, Santini V, Díez-Campelo M, Finelli C, Cazzola M, Ilhan O, Sekeres MA, Falantes JF, Arrizabalaga B, Salvi F, Giai V, Vyas P, Bowen D, Selleslag D, DeZern AE, Jurcic JG, Germing U, Götze KS, Quesnel B, Beyne-Rauzy O, Cluzeau T, Voso MT, Mazure D, Vellenga E, Greenberg PL, Hellström-Lindberg E, Zeidan AM, Adès L, Verma A, Savona MR, Laadem A, Benzohra A, Zhang J, Rampersad A, Dunshee DR, Linde PG, Sherman ML, Komrokji RS, List AF. Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes. The New England Journal Of Medicine 2020, 382: 140-151. PMID: 31914241, DOI: 10.1056/NEJMoa1908892.
• Hypomethylating agent (HMA) therapy use and survival in older adults with Refractory Anemia with Excess Blasts (RAEB) in the United States (USA): a large propensity score-matched population-based study†.Davidoff AJ, Hu X, Bewersdorf JP, Wang R, Podoltsev NA, Huntington SF, Gore SD, Ma X, Zeidan AM. Hypomethylating agent (HMA) therapy use and survival in older adults with Refractory Anemia with Excess Blasts (RAEB) in the United States (USA): a large propensity score-matched population-based study†. Leukemia & Lymphoma 2020, 61: 1178-1187. PMID: 31878809, PMCID: PMC7735409, DOI: 10.1080/10428194.2019.1703970.
• Association of provider experience and clinical outcomes in patients with myelodysplastic syndromes receiving hypomethylating agents.Zeidan AM, Hu X, Zhu W, Stahl M, Wang R, Huntington SF, Giri S, Bewersdorf JP, Podoltsev NA, Gore SD, Ma X, Davidoff AJ. Association of provider experience and clinical outcomes in patients with myelodysplastic syndromes receiving hypomethylating agents. Leukemia & Lymphoma 2020, 61: 397-408. PMID: 31570040, PMCID: PMC7732188, DOI: 10.1080/10428194.2019.1663423.
• In vivo anti-tumor effect of PARP inhibition in IDH1/2 mutant MDS/AML resistant to targeted inhibitors of mutant IDH1/2.Gbyli R, Song Y, Liu W, Gao Y, Biancon G, Chandhok NS, Wang X, Fu X, Patel A, Sundaram R, Tebaldi T, Mamillapalli P, Zeidan AM, Flavell RA, Prebet T, Bindra RS, Halene S. In vivo anti-tumor effect of PARP inhibition in IDH1/2 mutant MDS/AML resistant to targeted inhibitors of mutant IDH1/2. Leukemia 2022, 36: 1313-1323. PMID: 35273342, PMCID: PMC9103411, DOI: 10.1038/s41375-022-01536-x.
• A Phase 1/2 Study of the Oral Janus Kinase 1 Inhibitors INCB052793 and Itacitinib Alone or in Combination With Standard Therapies for Advanced Hematologic Malignancies.Zeidan AM, Cook RJ, Bordoni R, Berenson JR, Edenfield WJ, Mohan S, Zhou G, Asatiani E, Srinivas N, Savona MR. A Phase 1/2 Study of the Oral Janus Kinase 1 Inhibitors INCB052793 and Itacitinib Alone or in Combination With Standard Therapies for Advanced Hematologic Malignancies. Clinical Lymphoma, Myeloma & Leukemia 2022, 22: 523-534. PMID: 35260349, DOI: 10.1016/j.clml.2022.01.012.
• Cost-effectiveness of liposomal cytarabine/daunorubicin in patients with newly diagnosed acute myeloid leukemia.Bewersdorf JP, Patel KK, Goshua G, Shallis RM, Podoltsev NA, Huntington SF, Zeidan AM. Cost-effectiveness of liposomal cytarabine/daunorubicin in patients with newly diagnosed acute myeloid leukemia. Blood 2022, 139: 1766-1770. PMID: 35298594, PMCID: PMC8931513, DOI: 10.1182/blood.2021014401.
• A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for higher-risk myelodysplastic syndromes.Zeidan AM, Boss I, Beach CL, Copeland WB, Thompson E, Fox BA, Hasle VE, Ogasawara K, Cavenagh J, Silverman LR, Voso MT, Hellmann A, Tormo M, O'Connor T, Previtali A, Rose S, Garcia-Manero G. A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for higher-risk myelodysplastic syndromes. Blood Advances 2022, 6: 2207-2218. PMID: 34972214, PMCID: PMC9006291, DOI: 10.1182/bloodadvances.2021005487.
• A phase 1b study of glasdegib + azacitidine in patients with untreated acute myeloid leukemia and higher-risk myelodysplastic syndromes.Sekeres MA, Schuster M, Joris M, Krauter J, Maertens J, Breems D, Gyan E, Kovacsovics T, Verma A, Vyas P, Wang ES, Ching K, O'Brien T, Gallo Stampino C, Ma WW, Kudla A, Chan G, Zeidan AM. A phase 1b study of glasdegib + azacitidine in patients with untreated acute myeloid leukemia and higher-risk myelodysplastic syndromes. Annals Of Hematology 2022 PMID: 35488900, DOI: 10.1007/s00277-022-04853-4.
• Prospective Comparison of Outcomes with Azacitidine and Decitabine in AML Patients Ineligible for Intensive Chemotherapy.Zeidan AM, Fenaux P, Gobbi M, Mayer J, Roboz GJ, Krauter J, Robak T, Kantarjian HM, Novak J, Jedrzejczak WW, Thomas X, Ojeda-Uribe M, Miyazaki Y, Min YH, Yeh SP, Brandwein JM, Gercheva LT, Demeter J, Griffiths EA, Yee KW, Issa JJ, Bewersdorf JP, Keer HN, Hao Y, Azab M, Döhner H. Prospective Comparison of Outcomes with Azacitidine and Decitabine in AML Patients Ineligible for Intensive Chemotherapy. Blood 2022 PMID: 35507690, DOI: 10.1182/blood.2022015832.
• Impact of Hypomethylating Agent Use on Hospital and Emergency Room Visits, and Predictors of Early Discontinuation in Patients With Higher-Risk Myelodysplastic Syndromes.Zeidan AM, Joshi N, Kale H, Wang WJ, Corman S, Salimi T, Epstein RS. Impact of Hypomethylating Agent Use on Hospital and Emergency Room Visits, and Predictors of Early Discontinuation in Patients With Higher-Risk Myelodysplastic Syndromes. Clinical Lymphoma, Myeloma & Leukemia 2022 PMID: 35614009, DOI: 10.1016/j.clml.2022.04.016.
• Are We Moving the Needle for Patients with TP53-Mutated Acute Myeloid Leukemia?Shallis RM, Bewersdorf JP, Stahl MF, Halene S, Zeidan AM. Are We Moving the Needle for Patients with TP53-Mutated Acute Myeloid Leukemia? Cancers 2022, 14 PMID: 35626039, DOI: 10.3390/cancers14102434.